Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMM01 in Refractory or Recurrent Hematologic Malignancy
NCT05860075Phase 1Terminated
- Sponsor
- ImmuneOnco
- Start
- Nov 2019
- Primary completion
- Oct 2022
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of timdarpacept in classic Hodgkin lymphoma, B cell lymphoma, Natural killer T-cell lymphoma (NKTL) and 3 more, sponsored by ImmuneOnco. Primary endpoints: Adverse Events and Serious Adverse Events at 48 weeks, Dose-limiting toxicities at 28 days and 1 more. Started Nov 2019; status: terminated.
02
Drugs
timdarpacept
03
Conditions
classic Hodgkin lymphomaB cell lymphomaNatural killer T-cell lymphoma (NKTL)acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT05860075.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05860075.